399 related articles for article (PubMed ID: 16159932)
1. 1,25-dihydroxyvitamin D suppresses circulating levels of parathyroid hormone in a patient with primary hyperparathyroidism and coexistent sarcoidosis.
Kinoshita Y; Taguchi M; Takeshita A; Miura D; Tomikawa S; Takeuchi Y
J Clin Endocrinol Metab; 2005 Dec; 90(12):6727-31. PubMed ID: 16159932
[TBL] [Abstract][Full Text] [Related]
2. Overproduction of an amino-terminal form of PTH distinct from human PTH(1-84) in a case of severe primary hyperparathyroidism: influence of medical treatment and surgery.
Räkel A; Brossard JH; Patenaude JV; Albert C; Nassif E; Cantor T; Rousseau L; D'Amour P
Clin Endocrinol (Oxf); 2005 Jun; 62(6):721-7. PubMed ID: 15943835
[TBL] [Abstract][Full Text] [Related]
3. Plasma 25-hydroxyvitamin D and not 1,25-dihydroxyvitamin D is associated with parathyroid adenoma secretion in primary hyperparathyroidism: a cross-sectional study.
Moosgaard B; Vestergaard P; Heickendorff L; Melsen F; Christiansen P; Mosekilde L
Eur J Endocrinol; 2006 Aug; 155(2):237-44. PubMed ID: 16868136
[TBL] [Abstract][Full Text] [Related]
4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
5. Tubular calcium reabsorption and other aspects of calcium homeostasis in primary and secondary hyperparathyroidism.
Phelps KR; Stote KS; Mason D
Clin Nephrol; 2014 Aug; 82(2):83-91. PubMed ID: 24985952
[TBL] [Abstract][Full Text] [Related]
6. Coexisting primary hyperparathyroidism and sarcoidosis cause increased angiotensin-converting enzyme and decreased parathyroid hormone and phosphate levels.
Lim V; Clarke BL
J Clin Endocrinol Metab; 2013 May; 98(5):1939-45. PubMed ID: 23493435
[TBL] [Abstract][Full Text] [Related]
7. Reduced parathyroid hormone-stimulated 1,25-dihydroxyvitamin d production in vitamin d sufficient postmenoposual women with low bone mass and idiopathic secondary hyperparathyroidism.
Streeten EA; Rogstad AS; Flammer KM; Zarbalian K; Ryan K; Horwitz M; Holick MF; Shelton J
Endocr Pract; 2013; 19(1):91-9. PubMed ID: 23186957
[TBL] [Abstract][Full Text] [Related]
8. Hypercalcemia in a patient with primary hyperparathyroidism and acromegaly: distinct roles of growth hormone and parathyroid hormone in the development of hypercalcemia.
Ueda M; Inaba M; Tahara H; Imanishi Y; Goto H; Nishizawa Y
Intern Med; 2005 Apr; 44(4):307-10. PubMed ID: 15897641
[TBL] [Abstract][Full Text] [Related]
9. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
10. Influence of vitamin D on parathyroid function in the elderly.
Quesada JM; Coopmans W; Ruiz B; Aljama P; Jans I; Bouillon R
J Clin Endocrinol Metab; 1992 Aug; 75(2):494-501. PubMed ID: 1639950
[TBL] [Abstract][Full Text] [Related]
11. Suppressibility of parathyroid hormone in primary hyperparathyroidism.
Khoo TK; Baker CH; Abu-Lebdeh HS; Wermers RA
Endocr Pract; 2007; 13(7):785-9. PubMed ID: 18194938
[TBL] [Abstract][Full Text] [Related]
12. Primary hyperparathyroidism and severe hypercalcemia with low circulating 1,25-dihydroxyvitamin D.
Shaker JL; Krawczyk KW; Findling JW
J Clin Endocrinol Metab; 1990 Nov; 71(5):1305-9. PubMed ID: 2229288
[TBL] [Abstract][Full Text] [Related]
13. Alterations in serum and urine parameters reflecting bone turnover in uremic patients during treatment with 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3.
Mortensen BM; Gordeladze JO; Lyngdal PT; Aarseth HP; Gautvik KM
Miner Electrolyte Metab; 1993; 19(2):78-85. PubMed ID: 8377728
[TBL] [Abstract][Full Text] [Related]
14. Oral vitamin D supplementation reduces the incidence of eucalcemic PTH elevation after surgery for primary hyperparathyroidism.
Beyer TD; Solorzano CC; Prinz RA; Babu A; Nilubol N; Patel S
Surgery; 2007 Jun; 141(6):777-83. PubMed ID: 17560254
[TBL] [Abstract][Full Text] [Related]
15. Effect of aminohydroxypropylidene diphosphonate on the bone metabolism of patients with parathyroid adenoma.
Ishimura E; Miki T; Koyama H; Harada K; Nakatsuka K; Inaba M; Nishizawa Y; Morii H
Horm Metab Res; 1993 Sep; 25(9):493-7. PubMed ID: 8225204
[TBL] [Abstract][Full Text] [Related]
16. Plasma 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and parathyroid hormone in familial hypocalciuric hypercalcemia and primary hyperparathyroidism.
Christensen SE; Nissen PH; Vestergaard P; Heickendorff L; Rejnmark L; Brixen K; Mosekilde L
Eur J Endocrinol; 2008 Dec; 159(6):719-27. PubMed ID: 18787045
[TBL] [Abstract][Full Text] [Related]
17. Coexisting primary hyperparathyroidism and sarcoidosis in a patient with severe hypercalcemia.
Yoshida T; Iwasaki Y; Kagawa T; Sasaoka A; Horino T; Morita T; Hashimoto K
Endocr J; 2008 May; 55(2):391-5. PubMed ID: 18385529
[TBL] [Abstract][Full Text] [Related]
18. Calcitropic hormones and IGF-I are influenced by dietary protein.
Dubois-Ferrière V; Brennan TC; Dayer R; Rizzoli R; Ammann P
Endocrinology; 2011 May; 152(5):1839-47. PubMed ID: 21343254
[TBL] [Abstract][Full Text] [Related]
19. Bone Mineral Accrual Is Associated With Parathyroid Hormone and 1,25-Dihydroxyvitamin D Levels in Children and Adolescents.
DeBoer MD; Weber DR; Zemel BS; Denburg MR; Herskovitz R; Long J; Leonard MB
J Clin Endocrinol Metab; 2015 Oct; 100(10):3814-21. PubMed ID: 26241322
[TBL] [Abstract][Full Text] [Related]
20. Calciotropic hormones and bone markers in the elderly.
Gallagher JC; Kinyamu HK; Fowler SE; Dawson-Hughes B; Dalsky GP; Sherman SS
J Bone Miner Res; 1998 Mar; 13(3):475-82. PubMed ID: 9525348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
